HIV+Hepatitis Policy Institute will convene a panel on Friday, April 19, 2024, at the Biomedical HIV Prevention Summit to examine how PrEP is provided today by entities including community health centers, CBOs, pharmacies, telemedicine platforms, and state health departments. We will examine how this work is financed by leveraging existing programs and systems, as well as current barriers and what can be done to close PrEP access gaps in underserved populations.
North Carolina Blue Cross Blue Shield HIV Drug Tiers
Carl Schmid discusses NC Blue Cross Blue Shield’s decision to remove HIV drugs from the highest and costliest drug tiers following a discrimination complaint filed by the HIV+Hepatitis Policy Institute and NC AIDS Action Network.
Braidwood v Becerra: Amicus Briefs
Carl Schmid and Kevin Herwig offer updates at USCHA on Braidwood v Becerra, which challenges ACA’s preventive services coverage requirement, and discuss the amicus brief filed by HIV+Hepatitis Policy Institute and supported by 24 HIV and hepatitis organizations and other amici briefs filed by other groups.
Patients still face difficulties in accessing PrEP for free
Carl Schmid speaks with “Houston Matters” radio, along with a San Antonio, Texas PrEP client, about private insurers continuing to charge cost-sharing for PrEP and associated services and its impact on PrEP uptake.
The social determinants affecting PrEP use and access
Carl Schmid and Dr. Milgram discusses the disparities in education and access to PrEP in the patient populations that need these medications the most.